Indications

• Constipation (see Constipation, [[Constipation]])
• Irritable Bowel Syndrome (IBS) (see Irritable Bowel Syndrome, [[Irritable Bowel Syndrome]])

---

Pharmacology

• xxx

---

Administration

• xxxx

Dose Adjustment

• Hepatic:
• Renal:

---

Adverse Effects

Cardiovascular/Neurologic Adverse Effects

• Increased Risk of Cardiovascular Events: stroke, myocardial infarction
  • Novartis withdrew tegaserod in 2007 after FDA request
  • Although the relationship between tegaserod and this cardiovascular events was not supported in a large cohort study based on a US health insurance database

Gastrointestinal Adverse Effects

• Colonic Ischemia (see Colonic Ischemia, [[Colonic Ischemia]])

Other Adverse Effects

• xxx
• xxx
• xxx

---

References

• xxxx